Author

B. Walter

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Heuser· 1 shared A. Rosenwald· 1 shared B. Wollert-Wulf· 1 shared C. Farre Diaz· 1 shared C. Roggia· 1 shared D. Beule· 1 shared D. E. Root· 1 shared D. J. Merk· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Heuser

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Preclinical models of human multiple myeloma subgroups

W. Winkler, C. Farre Diaz, E. Blanc, H. Napieczynska, P. Langner, M. Werner, B. Walter, B. Wollert-Wulf, T. Yasuda, A. Heuser, D. Beule, S. Mathas, I. Anagnostopoulos, A. Rosenwald, K. Rajewsky, M. Janz

This study generates preclinical models of human multiple myeloma subgroups by inducing specific genetic alterations in mice, showing their resemblance to human disease.

bioRxiv · Aug 28, 2021 · PreprintCancer Biology

Genome-wide CRISPR and small-molecule screens uncover targetable dependencies in ATRT

D. J. Merk, S. Hirsch, F. Tsiami, B. Walter, L. A. Haeusser, S. Babaei, J. Admar, N. Casadei, C. Roggia, M. Spohn, J. Schittenhelm, S. Singer, U. Schueller, F. Piccioni, N. S. Persky, , G. Tabatabai

This study identifies targetable genetic dependencies in ATRT using CRISPR and small-molecule screens, revealing CDK4/6 inhibitors as potent therapeutic options.

bioRxiv · Dec 9, 2020 · PreprintCancer Biology